布-加综合征模型的构建及进展

王立博; 孙玉岭

doi:10.3969/j.issn.1001-5256.2020.04.044

布-加综合征模型的构建及进展

DOI: 10.3969/j.issn.1001-5256.2020.04.044

1. 郑州大学第一附属医院肝胆胰外科
2. 郑州大学肝胆胰疾病研究所
3. 郑州市肝胆胰疾病基础与临床研究重点实验室

基金项目:

国家自然科学基金项目(81870457,81900558)；

详细信息

中图分类号: R575;R-332
计量
- 文章访问数: 806
- HTML全文浏览量: 45
- PDF下载量: 269
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

Establishment of Budd-Chiari syndrome models and related research advances

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University

Research funding:

摘要

摘要: 布-加综合征是由肝静脉或其开口以上的下腔静脉阻塞引起的门静脉高压伴或不伴有下腔静脉高压的临床综合征,中国人群主要以下腔静脉隔膜形成和（或）阶段性合并肝静脉梗阻为特征。目前人们对布-加综合征的病因和发病机制所知甚少,所做研究多为诊治策略方面的临床研究,针对其发病机制的实验探索相对稀缺,而稳定模型往往是疾病机制研究的必要条件。就目前布-加综合征模型的构建方法、各种模型的特点和研究进展作一综述和分析,以便为该病病因和发病机制的探索提供可靠的实验基础。
- Budd-Chiari综合征 /
- 高血压,门静脉 /
- 疾病模型,动物
Abstract: Budd-Chiari syndrome( BCS) is a clinical syndrome of portal hypertension caused by the occlusion of the hepatic vein or the inferior vena cava,with or without inferior vena cava hypertension,and the formation of inferior vena cava diaphragm and/or hepatic venous obstruction are the main features in the Chinese population. At present,little is known about the etiology and pathogenesis of BCS,and most of the studies are clinical studies of diagnosis and treatment strategies. There is a lack of experimental exploration and research on the pathogenesis of BCS,and stable models are a necessary condition for the research on pathogenesis. This article reviews and analyzes the methods for establishing BCS models,the features of each model,and related research advances,in order to provide a reliable experimental basis for the research on the etiology and pathogenesis of BCS.
- Budd-Chiari syndrome /
- hypertension,portal /
- disease models,animal

HTML全文

参考文献(28)

[1] HERNANDEZ-GEA V,de GOTTARDI A,LEEBEEK FWG,et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis[J]. J Hepatol,2019,71(1):175-199.

[2] DING PX,HAN XW,LIU C,et al. Long-term outcomes of individualized treatment strategy in treatment of type I BuddChiari syndrome in 456 patients[J]. Liver Int,2019,39(8):1577-1586.

[3] MUKUND A,SARIN SK. Budd-Chiari syndrome:A focussed and collaborative approach[J]. Hepatol Int,2018,12(6):483-486.

[4] KHAN F,ARMSTRONG MJ,MEHRZAD H,et al. Review article:A multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome[J]. Aliment Pharmacol Ther,2019,49(7):840-863.

[5] LI J,MA XX,SUN YL,et al. Establishment of Budd-Chiari syndrome model in rat[J]. Chin J Bases Clin General Surg,2013,20(5):477-480.(in Chinese)李健，马秀现，孙玉岭，等．布-加综合征大鼠动物模型的建立[J]．中国普外基础与临床杂志，2013,20(5):477-480.

[6] QI X,HAN G,GUO X,et al. Review article:The aetiology of primary Budd-Chiari syndrome-differences between the West and China[J]. Aliment Pharmacol Ther,2016,44(11-12):1152-1167.

[7] WU KM,CAO S,ZHANG GY,et al. A case of paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome as the first manifestation[J]. J Clin Hepatol,2018,34(10):2197-2199.(in Chinese)巫凯敏，曹珊，张国艳，等．以布加综合征为首发表现的阵发性睡眠性血红蛋白尿症1例报告[J]．临床肝胆病杂志，2018,34(10):2197-2199.

[8] LIU DH,XIA XW,YE TH,et al. The effect of CT/MR in evaluating obstructive characteristics and interventional therapy related risk factors in patients with inferior vena cava obstruction[J]. Diagn Imag Interv Radiol,2019,28(1):21-26.(in Chinese)刘德翰，夏向文，叶天和，等．下腔静脉梗阻的CT/MR特征与介入治疗相关危险因素评估[J]．影像诊断与介入放射学，2019,28(1):21-26.

[9] WANG QH,LI K,HE CY,et al. Angioplasty with versus without routine stent placement for Budd-Chiari syndrome:A randomised controlled trial[J]. Lancet Gastroenterol Hepatol,2019,4(9):686-697.

[10] QI XS,REN WR,FAN DM,et al. Selection of treatment modalities for Budd-Chiari Syndrome in China:A preliminary survey of published literature[J]. World J Gastroenterol,2014,20(30):10628-10636.

[11] HAYEK G,RONOT M,PLESSIER A,et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary BuddChiari syndrome[J]. Radiology,2017,283(1):280-292.

[12] SUN YL,MA XX,FENG LS,et al. Compensation by collateral circulation determines invasive therapeutic indications for patients with Budd-Chiari syndrome[J]. Gut,2012,61(12):1779-1780.

[13] FU Y,SUN YL,MA XX,et al. Necessity and indications of invasive treatment for Budd-Chiari syndrome[J]. Hepatobiliary Pancreat Dis Int,2011,10(3):254-260.

[14] VALLA DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int,2018,12(Suppl 1):168-180.

[15] MAGUIRE R,DOPPMAN JL. Angiographic abnormalities in partial Budd-Chiari syndrome[J]. Radiology,1977,122(3):629-635.

[16] BAI DQ,ZHAN F,ZHENG Y. An animal model with ascites due to hepatic vein resistance[J]. Chin J Lab Anim Sci,2002,12(1):28-30.(in Chinese)白殿卿，詹峰，郑颖．犬肝静脉阻力制做腹水实验模型的改进[J]．中国实验动物学杂志，2002,12(1):28-30.

[17] WANG CX,LIANG FQ,HAN LN,et al. Establishment of the Budd-Chiari syndrome model through laser photocoagulation[J]. Chin J Laser Med Surg,2005,14(1):9-11.(in Chinese)王春喜，梁发启，韩丽娜，等．利用腔内激光技术制作肝静脉阻塞性布加氏综合征模型的探讨[J]．中国激光医学杂志，2005,14(1):9-11.

[18] CHEN SY,GAO Y,YU CW,et al. A canine model for IVC occlusive form of Budd-Chiari syndrome using endovascular technique[J]. Cell Biochem Biophys,2013,67(3):1513-1519.

[19] SHEN B,ZHANG QQ,WANG XL,et al. Development of a canine model with diffuse hepatic vein obstruction(Budd-Chiari syndrome)via endovascular occlusion[J]. Mol Med Rep,2014,9(2):607-613.

[20] MURAD SD,DOM VA,RITMAN EL,et al. Early changes of the portal tract on microcomputed tomography images in a newly-developed rat model for Budd-Chiari syndrome[J].J Gastroenterol Hepatol,2008,23(10):1561-1566.

[21] CHENG DL,ZHU N,LI CL,et al. Significance of malondialdehyde,superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model[J]. Exp Ther Med,2018,16(6):5227-5235.

[22] GAO B,LI C,LIU P. Establishment of a mouse model of acute Budd-Chiari syndrome and expression of protease-activated receptor-1 in liver,spleen and kidneytissues[J]. J Med Pest Control,2019,35(12):1168-1172.(in Chinese)高兵，李晨，刘沛．急性布加综合征小鼠模型的建立及其肝脾肾组织中蛋白酶激活受体-1的表达[J]．医学动物防制，2019,35(12):1168-1172.

[23] CHENG DQ,ZHUANG YP,KOU QQ,et al. Numerical simulation of hemodynamics in membranous obstruction of the suprahepatic inferior vena cava based on a subject-specific Budd-Chiari syndrome model[J]. Clin Biomech(Bristol,Avon),2018,52:20-24.

[24] HO H,QIU C. Hemodynamic aspects of the Budd-Chiari syndrome of the liver:A computational model study[J]. Med Eng Phys,2019,69:134-139.

[25] TURJMAN AS,TURJMAN F,EDELMAN ER. Role of fluid dynamics and inflammation in intracranial aneurysm formation[J]. Circulation,2014,129(3):373-382.

[26] YAMAMOTO E,THONDAPU V,POON E,et al. Endothelial Shear stress and plaque erosion:A computational fluid dynamics and optical coherence tomography study[J]. JACC Cardiovasc Imaging,2019,12(2):374-375.

[27] CAZALS-HATEM D,VILGRAIN V,GENIN P,et al. Arterial and portal circulation and parenchymal changes in BuddChiari syndrome:A study in 17 explanted livers[J]. Hepatology,2003,37(3):510-519.

[28] MANCUSO A. Budd-Chiari syndrome hemodynamic:Clinical setting more complicated than computational model[J]. Med Eng Phys,2019,71:1.

施引文献

资源附件(0)

访问统计